[go: up one dir, main page]

BR9909717A - Fatores angiogênicos terapêuticos e métodos para seu uso - Google Patents

Fatores angiogênicos terapêuticos e métodos para seu uso

Info

Publication number
BR9909717A
BR9909717A BR9909717-6A BR9909717A BR9909717A BR 9909717 A BR9909717 A BR 9909717A BR 9909717 A BR9909717 A BR 9909717A BR 9909717 A BR9909717 A BR 9909717A
Authority
BR
Brazil
Prior art keywords
poly
angiogenic factor
vehicle
pleiotropin
animal
Prior art date
Application number
BR9909717-6A
Other languages
English (en)
Inventor
Kenneth J Colley
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Publication of BR9909717A publication Critical patent/BR9909717A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"FATORES ANGIOGêNICOS TERAPêUTICOS E MéTODOS PARA SEU USO"<D>. São proporcionados métodos para estimulação da angiogênese em um ser humano ou animal que precise da mesma. Também são proporcionadas composições compreendendo o fator angiogênico em um veículo farmaceuticamente aceitável. Em uma concretização, o método compreende a administração ao ser humano ou outro animal de uma quantidade terapeuticamente efetiva de um fator angiogênico, tal como uma proteína de pleiotropina ou midkine, em um veículo farmaceuticamente aceitável. O veículo, em uma concretização, compreende uma matriz de liberação controlada, tal como um polímero, que permite a liberação controlada do fator angiogênico. O polímero pode ser biodegradável e/ou biodesgastável e de preferência biocompatível. Polímeros os quais podem ser usados para liberação controlada incluem, por exemplo, poli ( esteres), poli (anidridos) e poli (aminoácidos). Polímeros exemplificativos incluem copolímeros em blocos de poli (aminoácido) de elastina de seda e poli-lactídeo-co-glicolídeo. Em uma outra concretização, o fator angiogênico pode ser proporcionado em um veículo compreendendo um lipossoma, tal como um lipossoma hetero-vesicular. O veículo, tal como lipossoma, pode ser proporcionado com um ligante de objetivação capaz de levar o veículo a um local pré-selecionado no corpo. O fator angiogênico pode ser administrado ao sistema vascular, por exemplo, o sistema cardiovascular ou ao sistema vacular periférico. Em uma concretização preferida, o fator angiogênico é uma proteína de pleiotropina ou uma protéina midkine. Em outra concretização, é proporcionado um método para estimulação da angiogênese em um ser humano ou animal compreendendo a administração de uma quantidade terapeuticamente efetiva de um vetor de transferência de gene que codifica a produção de uma proteína de pleiotropina ou midkine em um veículo farmaceuticamente aceitável. O vetor de transferência de gene pode ser, por exemplo, DNA nu ou um vetor viral, e pode ser administrado, por exemplo, em combinação com lipossomas.
BR9909717-6A 1998-04-17 1999-04-16 Fatores angiogênicos terapêuticos e métodos para seu uso BR9909717A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8215598P 1998-04-17 1998-04-17
PCT/US1999/008420 WO1999053943A2 (en) 1998-04-17 1999-04-16 Therapeutic angiogenic factors and methods for their use

Publications (1)

Publication Number Publication Date
BR9909717A true BR9909717A (pt) 2000-12-26

Family

ID=22169397

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909717-6A BR9909717A (pt) 1998-04-17 1999-04-16 Fatores angiogênicos terapêuticos e métodos para seu uso

Country Status (11)

Country Link
US (2) US20030185794A1 (pt)
EP (1) EP1071445A2 (pt)
JP (1) JP2002512200A (pt)
CN (1) CN1379681A (pt)
AU (1) AU760664B2 (pt)
BR (1) BR9909717A (pt)
CA (1) CA2329010A1 (pt)
IL (1) IL139030A0 (pt)
MX (1) MXPA00010110A (pt)
NO (1) NO20005190L (pt)
WO (1) WO1999053943A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
AU3471400A (en) * 1999-01-19 2000-08-07 Children's Hospital Of Philadelphia, The Compositions and methods for controlled delivery of virus vectors
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
RU2245722C2 (ru) * 1999-06-22 2005-02-10 Рисерч Дивелопмент Фаундейшн Усовершенствованное раневое покрытие для улучшения заживления ран
JP2001064196A (ja) * 1999-08-24 2001-03-13 Meiji Milk Prod Co Ltd 創傷治癒促進組成物
US6364912B1 (en) 1999-09-17 2002-04-02 Depuy Orthopeaedics, Inc. Pleiotrophin-based compositions for enhancing connective tissue repair
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
IL151501A0 (en) 2000-03-15 2003-04-10 Orbus Medical Technologies Inc Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
DE60141518D1 (de) * 2000-06-14 2010-04-22 Univ Georgetown Pleiotrophin wachstumfaktor rezeptor alk zur behandlung von proliferativen, gefässer- und neurologischen erkrankungen
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US6939540B1 (en) * 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
GB0113697D0 (en) 2001-06-06 2001-07-25 Smith & Nephew Fixation devices for tissue repair
CA2491052A1 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
WO2004060424A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Silk-containing stent graft
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
JP4850709B2 (ja) * 2003-05-14 2012-01-11 ダニスコ・ユーエス・インコーポレーテッド 反復配列タンパク質ポリマーを使用する、活性剤の制御放出
US20080039382A1 (en) * 2003-05-29 2008-02-14 Lee Randall J Compositions related to pleiotrophin methods and uses thereof
EP1644027B1 (en) 2003-07-16 2014-04-09 Evotec International GmbH Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
CA2535029C (en) 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20060085062A1 (en) * 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
TW200605910A (en) * 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
WO2006042197A2 (en) * 2004-10-11 2006-04-20 The Board Of Trustees Of The Leland Standford Junior University Use of del-1 in hair, bone and cartilage regeneration
JP4791770B2 (ja) 2004-12-06 2011-10-12 株式会社セルシグナルズ 心筋障害又は心不全の治療もしくは予防組成物
US7595295B2 (en) * 2005-02-25 2009-09-29 Rush University Medical Center Use of pleiotrophin to promote neurogeneration
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
TWI486168B (zh) 2006-09-22 2015-06-01 Univ Texas 治療內皮功能不良之方法
JPWO2008047904A1 (ja) * 2006-10-20 2010-02-25 国立大学法人名古屋大学 閉塞性末梢血管疾患治療剤、およびその利用
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
JPWO2008129851A1 (ja) 2007-03-30 2010-07-22 国立大学法人名古屋大学 一酸化窒素合成酵素活性化剤
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
CN101601858B (zh) * 2009-05-27 2012-09-19 上海交通大学 中期因子蛋白的用途及含该蛋白的医用装置
EP2538963B8 (en) * 2010-02-24 2017-08-02 Advangen International Pty Ltd Method of treatment or prevention of hair loss or for the enhancement of hair growth
CN102965387A (zh) * 2012-10-25 2013-03-13 中国科学院广州生物医药与健康研究院 Trx-hPTN融合蛋白及其生产方法
BR112015028367B1 (pt) * 2013-05-15 2020-12-01 The Board Of Trustees Of The Leland Stanford Junior University agente que provê atividade de fator de crescimento de epiderme de ligação de heparina (hb-egf), formulação farmacêutica para tratamento de perfuração crônica de membrana de tímpano e uso destes
EP3740211A4 (en) * 2018-01-18 2021-04-14 Endoprotech, Inc TREATMENT OF MICROVASCULAR DISORDERS

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465189A (en) * 1891-12-15 Overshoe attachment
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4369229A (en) * 1981-01-29 1983-01-18 The Kendall Company Composite hydrogel-forming article and method of making same
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4720507A (en) * 1984-03-05 1988-01-19 University Of Western Ontario Biological contraceptive and contraceptive technique for males
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4699788A (en) * 1984-08-20 1987-10-13 Trustees Of Boston University Angiogenic factor methods of extraction and method for producing angiogenesis
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4547784A (en) * 1984-12-24 1985-10-15 Polaroid Corporation Thermal recording system and method
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5171842A (en) * 1988-01-25 1992-12-15 American Cyanamid Company Heparin-binding brain mitogens
US5270449A (en) * 1988-01-25 1993-12-14 American Cyanamid Company Methods for the isolation of heparin-binding brain mitogens
US5641743A (en) * 1988-01-25 1997-06-24 American Cyanamid Company Therapeutic compositions and methods for use of heparin-binding brain mitogens
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5576017A (en) * 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5475052A (en) * 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5527856A (en) * 1988-11-21 1996-06-18 Collagen Corporation Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5041497A (en) * 1989-04-10 1991-08-20 Allied-Signal Inc. Process for preparing co-poly(amides/peptides)
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
DE69018357T2 (de) * 1989-10-06 1995-09-21 President Of National Cancer C Mutein von HST-1 und seine Herstellung.
US6448381B1 (en) * 1990-01-08 2002-09-10 Barnes-Jewish Hospital DNA encoding heparin-binding growth factor
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
EP0486862B1 (en) * 1990-11-23 1996-05-29 American Cyanamid Company Chimeric fibroblast growth factor
US5206354A (en) * 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2
EP0488196A3 (en) * 1990-11-30 1993-04-07 Takeda Chemical Industries, Ltd. Hst-2, a member of the heparin binding growth factor family
US5540928A (en) * 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
FR2692582B1 (fr) * 1992-06-18 1998-09-18 Flamel Tech Sa Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux.
US5469505A (en) * 1992-07-08 1995-11-21 Acs Wireless, Inc. Communications headset having a ball joint-mounted receiver assembly
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
FR2701955B1 (fr) * 1993-02-26 1995-05-24 Paris Val Marne Universite Facteur de croissance de la famille de l'HARP, procédé d'obtention et applications.
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5491220A (en) * 1993-09-24 1996-02-13 Yeda Research And Development Co., Ltd. Surface loop structural analogues of fibroblast growth factors
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5540657A (en) * 1994-07-15 1996-07-30 Collagen Corporation Delivery device for injectable materials
WO1996002257A1 (en) * 1994-07-18 1996-02-01 Georgetown University Antisense oligonucleotides of pleiotrophin
JPH0827021A (ja) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc 医薬組成物
US5582937A (en) * 1994-10-12 1996-12-10 Bipolar Technologies, Inc. Bipolar battery cells, batteries and methods
US5551427A (en) * 1995-02-13 1996-09-03 Altman; Peter A. Implantable device for the effective elimination of cardiac arrhythmogenic sites
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
ATE330620T1 (de) * 1997-07-14 2006-07-15 Takashi Muramatsu Verwendung von midkin oder von anti-midkin antikörper
KR100554294B1 (ko) * 1997-09-26 2006-02-24 무라마쯔 다카시 허혈성 질환의 예방 또는 치료제
US6364912B1 (en) * 1999-09-17 2002-04-02 Depuy Orthopeaedics, Inc. Pleiotrophin-based compositions for enhancing connective tissue repair

Also Published As

Publication number Publication date
US20030185794A1 (en) 2003-10-02
WO1999053943A3 (en) 2000-01-20
AU3495599A (en) 1999-11-08
IL139030A0 (en) 2001-11-25
WO1999053943A2 (en) 1999-10-28
EP1071445A2 (en) 2001-01-31
US20030202960A1 (en) 2003-10-30
AU760664B2 (en) 2003-05-22
MXPA00010110A (es) 2002-08-06
JP2002512200A (ja) 2002-04-23
CA2329010A1 (en) 1999-10-28
NO20005190L (no) 2000-11-30
NO20005190D0 (no) 2000-10-16
CN1379681A (zh) 2002-11-13

Similar Documents

Publication Publication Date Title
BR9909717A (pt) Fatores angiogênicos terapêuticos e métodos para seu uso
Mfoafo et al. Thiolated polymers: An overview of mucoadhesive properties and their potential in drug delivery via mucosal tissues
Nabel et al. Gene transfer in vivo with DNA–liposome complexes: lack of autoimmunity and gonadal localization
US20080107720A1 (en) Topical delivery of codrugs
NZ507185A (en) Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
PT957900E (pt) Composicoes e metodos para aplicacao topica de agentes terapeuticos
US20100144618A1 (en) Compositions containing an intestinal trefoil peptide and a mucoadhesive
BR9915919A (pt) Proteìnas terapeuticamente ativas em plantas
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
EP2286799A3 (en) Microspheres for active embolization
EP1183538A4 (en) CYCLODEXTRIN POLYMERS FOR USE AS MEDICAMENT VECTORS
US7538082B2 (en) Methods and compositions for treating oral and esophageal lesions
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
EP1723976A3 (en) Intraluminal medical devices in combination with therapeutic agents
EP1383527A1 (en) Methods and compositions for treating oral and esophageal lesions
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
DE69836384D1 (de) Antisense-oligonukleotide gegen thymidylatsynthase
JP2002145784A (ja) 生物学的活性薬剤導入組成物およびその使用方法
DE60041004D1 (de) Abführzusammensetzung,welche l-arginine enthält
ES2732669T3 (es) Tratamiento de la esclerosis múltiple
BR9810095A (pt) Dispositivos para distribuição de droga e métodospara tratamento de infecções virais e microbianase de sìndromes de emaciação
EP1842858A2 (en) Methods and compositions for treating oral and esophageal lesions
AU2002307512A1 (en) Methods and compositions for treating oral and eosophageal Lesions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O,6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.